Results 311 to 320 of about 1,066,380 (380)
ABSTRACT Background As a cardiac interventional procedure, percutaneous coronary intervention (PCI) is increasingly becoming the most widely adopted across the globe. With increasing implementation in practice, the use of PCI registries to evaluate safety and effectiveness has grown internationally.
Vu Hoang Vu+6 more
wiley +1 more source
Recurrent acute myocardial infarction associated with calcified pseudoaneurysm: A case analysis. [PDF]
Gao ZL, Xie P, Zhou X, Li YL.
europepmc +1 more source
ABSTRACT Background Intravascular lithotripsy (IVL) has emerged as a promising treatment for heavily calcified coronary lesions. However, evidence regarding its effectiveness in calcific bifurcation lesions remains limited. Objective We aimed to evaluate the technical success and 1‐year clinical outcomes of IVL in calcified coronary bifurcation lesions.
Federico Oliveri+15 more
wiley +1 more source
Iron Deficiency as a Factor of Worse Prognosis in Patients with Acute Myocardial Infarction. [PDF]
Misiewicz A+4 more
europepmc +1 more source
Two types of carbon quantum dots (CQD‐COOH and CQD‐NH2) are used to modify screen printed carbon electrodes, for detection of Cardiac Troponin I (cTnI). These modified sensors offer promising results for the determination of cTnI in the picomolar range, when, using an immunosensor protocol.
Yemataw Addis Alemu+4 more
wiley +1 more source
Lipid alterations in acute myocardial infarction are associated with gut microbiota. [PDF]
Zuo J+10 more
europepmc +1 more source
Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions.
James M. Stevenson+4 more
wiley +1 more source
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith+18 more
wiley +1 more source
Prodromal Symptoms of Acute Myocardial Infarction in Women: A Systematic Review of Current Evidence. [PDF]
Giordano V+4 more
europepmc +1 more source
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier+20 more
wiley +1 more source